Guardant Health (GH) Earns “Outperform” Rating from William Blair
Several other equities analysts have also recently commented on GH. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $42.00 to $85.00 and gave the stock an overweight rating in a research report on Wednesday. Bank of America reiterated a neutral rating and set a $60.00 price objective (up previously from $42.00) on shares of Guardant Health in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Guardant Health presently has an average rating of Buy and a consensus target price of $72.50.
Shares of GH stock opened at $97.98 on Wednesday. Guardant Health has a one year low of $27.04 and a one year high of $106.58. The stock has a market cap of $8.48 billion and a PE ratio of -34.99.
In other Guardant Health news, major shareholder Vision Fund (Aiv M1) Softbank acquired 2,033,990 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The shares were purchased at an average price of $9.83 per share, for a total transaction of $19,994,121.70. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Several large investors have recently made changes to their positions in GH. Geode Capital Management LLC acquired a new position in Guardant Health in the 4th quarter worth approximately $8,278,000. Norges Bank acquired a new position in Guardant Health in the 4th quarter worth approximately $1,504,000. Financial Advocates Investment Management acquired a new position in Guardant Health in the 4th quarter worth approximately $220,000. FMR LLC acquired a new position in Guardant Health in the 4th quarter worth approximately $13,612,000. Finally, Legal & General Group Plc acquired a new position in Guardant Health in the 4th quarter worth approximately $85,000. Institutional investors own 69.54% of the company’s stock.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
See Also: 12b-1 Fees
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.